Tag:

NICE

Latest Headlines

Latest Headlines

NICE rejects Roche's hot new breast cancer drug Kadcyla, then invites negotiations

Let the price negotiations begin, the top executive for the U.K. price watchdog suggested today after the agency nixed Roche's pioneering breast cancer drug Kadcyla as too expensive.

British cost watchdog backtracks again on Roche's Tarceva

After intitially recommending Roche's targeted cancer drug Tarceva for use by Britain's National Health Service, the U.K.'s National Institute for Health and Care Excellence said in February it was reviewing the recommendation. Now, it looks likely to revert back to its original stance--a reversal of fortune the Swiss drugmaker is pleased with.

New NICE evals could green-light more drugs, but only at 'the very best price'

The U.K.'s cost watchdog is changing up the way it evaluates drugs. The National Institute for Health and Care Excellence (NICE) will be zooming out to look at the bigger picture when assessing therapies, which could result in more positive recommendations--something drugmakers have been dreaming of for years.

Even at a discount, Sanofi's pricey cancer drug Zaltrap can't win at NICE

The U.K.'s National Institute for Health and Care Excellence has spurned Sanofi's colon cancer treatment Zaltrap once again. And this time, the decision is final. The cost-effectiveness agency dismissed the French company's appeal, despite the offer of a discount.

Cost watchdogs demand efficacy data on new Bayer cancer drugs

German pharma giant Bayer got back-to-back bad news on two of its newest drugs, from two different countries, no less.

J&J's Velcade cleared by U.K. for first-line myeloma treatment in about-face

The U.K.'s National Institute for Health and Care Excellence has come around on Johnson & Johnson's Velcade as a first-line treatment for the blood cancer multiple myeloma. It approved the drug for the new use today, four months after initially saying it was unconvinced the benefits of the drug outweighed its costs.

Celgene's superstar Revlimid again dissed by U.K. cost watchdog

Celgene is working to expand its portfolio of drugs, but for now its growth is primarily driven by extending the uses of its megablockbuster Revlimid. As successful as the myeloma drug has been, the U.K.'s NICE is again questioning its cost vs. benefit for certain patients.

Why does Alexion's Soliris cost $500K-plus? U.K. gatekeepers want to know

It's fairly routine for the U.K.'s cost-effectiveness watchdogs to ask companies for more data to support approval for use by the country's National Health Service. Clinical data, price modeling, the works. But asking for information on R&D costs? That's something different altogether.

U.K. drug reviewers slam BMS' melanoma blockbuster but bless J&J's diabetes pill

The cost-effectiveness agency recommended that Bristol-Myers Squibb's widely embraced Yervoy (ipilimumab) should not be used as a first-line treatment for melanoma. The agency does recommend the drug for second-line treatment, but says BMS needs to do more clinical trials to prove its "clinical effectiveness" for earlier use.

Biogen Idec hits its first price hurdle for Tecfidera in the EU

Biogen Idec's hot-selling multiple sclerosis drug Tecfidera has to win reimbursement in individual European countries where governments have gotten stingy about parting with healthcare dollars. A decision Thursday by U.K. price watchdog NICE is an indication of the cost hurdles to be faced.